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disease definitions
Sharon Sanders* , Rae Thomas, Paul Glasziou and Jenny Doust
Abstract
Background: Widening definitions of health conditions have the potential to affect millions of people and should
only occur when there is strong evidence of benefit. In the last version of the Diagnostic and Statistical Manual of
Mental Disorders (DSM), the DSM-5 Committee changed the Attention Deficit Hyperactivity Disorder (ADHD) age of
onset criterion in two ways: raising the age of symptom onset and removing the requirement for symptoms to
cause impairment. Given concerns about ADHD prevalence and treatment rates, we aimed to evaluate the
evidence available to support these changes using a recently developed Checklist for Modifying Disease Definitions.
Methods: We identified and analysed research informing changes to the DSM-IV-TR ADHD age of onset criterion.
We compared this evidence to the evidence recommended in the Checklist for Modifying Disease Definitions.
Results: The changes to the DSM-IV-TR age of onset criterion were based on a literature review (publicly available
as a 2 page document with online table of included studies), which we appraised as at high risk of bias. Estimates
of the change in ADHD prevalence resulting from change to the age of onset criterion were based on a single
study that included only a small number of children with ADHD (n = 68) and only assessed the impact of change
to the age component of the criterion. No evidence was used by, or available to the Committee regarding the
impact on prevalence of removal of the requirement for impairment, or the effect of the criterion changes on
diagnostic precision, the prognosis of, or the potential benefits or harms for individuals diagnosed by the new, but
not old criterion.
Conclusions: The changes to the age of onset criterion were based on minimal research evidence that suffered
from either high risk of bias or poor applicability. The minimal documentation available makes it difficult to judge
the rigor of the process behind the criterion changes. Use of the Checklist for Modifying Disease Definitions would
assist future proposed modifications of the DSM ADHD criteria, provide guidance on the studies needed to inform
potential changes and would improve the transparency and documentation of the process.
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Background
When the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR) became DSM-5, the age of on-
set criterion for Attention Deficit Hyperactivity Disorder
(ADHD) changed from, ‘some hyperactive-impulsive or
inattentive symptoms that caused impairment were
present before age 7 years’ (DSM IV-TR), to ‘several in-
attentive or hyperactive-impulsive symptoms present
prior to age 12 years’ (DSM-5). The modification thus
comprised two changes: increasing the age of onset of
symptoms from before 7 years to before 12 years, and re-
moving the requirement for the “onset of symptoms
causing impairment” to the “onset of symptoms”. Both
changes widen the definition of ADHD and potentially
lead to the widening of treatment recommendations.
The increase in the prescribing of ADHD medications in
several countries in recent years is a possible conse-
quence of this widening, raising concerns about overdi-
agnosis [1–5].
In response to the widening of definitions of health
conditions observed across many disciplines [6], a check-
list and guide for those considering changes to disease
definitions has recently been published [7]. Rigorously
developed by a multidisciplinary, multicontinent author
group for the Guidelines International Network
Preventing Overdiagnosis working Group members, the
Checklist for Modifying Disease Definitions, provides a
framework of 8 items to guide the decision-making
process regarding the uncertainties and trade-offs in
modifying disease definitions (Table 1). Five checklist
items require the identification and analysis of research
studies to determine: potential changes in prevalence,
the prognostic ability, precision and accuracy, and the
incremental benefits and harms of the new definition.
The development of the checklist allows a rigorous ap-
praisal of the methods used when professional groups
change the definition of a health condition. Given the
concerns regarding the changes to the ADHD age of on-
set criterion, we used the Checklist for Modifying Dis-
ease Definitions, to examine changes to the diagnostic
criteria for ADHD from DSM IV-TR to DSM-5. While
the transition to DSM-5 involved changes to several of
the ADHD criteria (e.g. the elaboration of symptom cri-
terion and removal of exclusionary disorders criterion),
we focus only on modification to the age of onset criter-
ion. Our objectives were to; a) identify and appraise the
research used by the relevant DSM-5 Committee to in-
form the changes to the age of onset criterion; and b)
identify and evaluate any other research relating to the
criterion as recommended by the checklist.
Table 1 Checklist for Modifying Disease Definitions [7]
Checklist Item Rationale
1. Definition: What are the differences between the
previous and the new definition?
It is important to delineate the proposed
change precisely.
2. Number of people affected: How will the new
disease definition change the incidence and
prevalence of the disease?
The number of people affected is extremely
important in understanding benefits, harms
and resources needed.
3. Trigger: What is the trigger for considering the
modification of the disease definition?
Stating the trigger for considering modification
helps understand the necessity for modifying
the disease definition.
4. Prognostic ability: How well does the new
definition of disease predict clinically important
outcomes compared with the previous definition?
The most important feature of a disease
definition is its ability to accurately predict
clinically important outcomes.
5. Disease definition precision and accuracy: What
is the repeatability, reproducibility and accuracy
(when estimations are possible) of the new disease
definition?
Disease definitions that are repeatable and
reproducible improve the consistency of clinical
decision making. Accuracy is often not able to
be estimated because of the lack of a reference
standard.
6. Benefit: What is the incremental benefit for
patients classified by the new definition versus
the previous definition?
Benefits of the disease definition can be outlined,
using methods such as GRADE. It is particularly
important to estimate benefits in conditions where
the new definition will be used to determine
treatment thresholds.
7. Harm: What is the incremental harm for
patients classified by the new definition versus
the previous definition?
Harms may also be outlined using methods such
as GRADE. It is often more difficult to quantify harms,
and particularly the psychosocial harms and harms
on the societal level, including resource related harms.
8. Net benefit and harms: What is the net
benefit and harm for patients classified by
the new definition versus the previous
definition?
A panel should consider all the above, and the
balance of net benefits and harms prior to modifying
a disease definition.
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Methods
Identifying documents describing the proposed changes
and supportive evidence
We first sought to identify documents outlining the pro-
posed or actual changes to the DSM-IV-TR ADHD age
of onset criterion and the evidence used by the Commit-
tee to inform these changes. We searched websites and
bibliographic databases, asked manuscript authors’ and
colleagues for studies known to them, and conducted
reference checks, forward citation and PubMed “similar
articles” searches (Additional file 1: Table S1).
Identifying research to address checklist items
We then conducted a search for any further studies
available in the literature that could address the checklist
items requiring analysis of research studies (items 2, 4,
5, 6 and 7) and provide information to inform the pro-
posed change to the age of onset criterion. We searched
PubMed from 1990 to January 2013 using terms related
to ADHD and age of onset (Additional file 1: Table S2).
As DSM-5 was released in May 2013, we searched for
studies that would have been available to the Committee
up to and the end of January 2013. We performed refer-
ence checks and forward citations searches of relevant
papers. Titles and abstracts were screened by two au-
thors and potentially relevant studies were obtained in
full text for further review.
Classifying studies and analysing quality
Studies identified in both searches were independently
assessed by two authors (SS, RT) and based on the
study’s reported objectives (or first reported results if the
objectives were unclear), categorized according to the
checklist items as research relating to 1) prevalence, 2)
prognosis, 3) accuracy and/or precision, and 4) benefits
or harms. Studies not relating to these constructs were
not further assessed. Studies that were not primary re-
search studies (e.g. review articles), and studies con-
cerned with different DSM versions or populations were
also excluded from further assessment.
The quality of the studies addressing the checklist
items was assessed using relevant risk of bias tools. We
assessed the methodological quality of systematic re-
views using A Measurement Tool to Assess Systematic
Reviews (AMSTAR-2) [8]. For primary studies of preva-
lence, we used the risk of bias tool developed by Hoy
[9]. For studies assessing the measurement properties of
the age of onset criterion we used the QAREL appraisal
tool [10] and for studies assessing the prognostic ability
of the criterion we used the QUIPS tool [11]. To assess
risk of bias in studies reporting treatment benefit and
harm we used tools appropriate for the design of the
study.
We assessed the strength of the research evidence for
each Checklist item using elements from the Grading of
Recommendations, Assessment, Development and Eval-
uations (GRADE) approach [12]. These include study
design and limitations (e.g. risk of bias), the consistency
of the research evidence (e.g. the similarity in magnitude
and direction of results across studies of the same or
similar design), and the applicability of the evidence to
the Checklist question. To assess applicability we consid-
ered whether; prevalence studies evaluated the effect of
the change in the age of onset criterion (including both
age and impairment changes) on prevalence of ADHD;
prognostic studies evaluated the clinically relevant out-
comes of individuals diagnosed by the new, but not old
age of onset criterion (i.e. the ‘additional’ children classi-
fied using the new criterion); studies of diagnostic preci-
sion evaluated the repeatability of the criterion by the
same clinician at different times, or the reproducibility
of different clinicians using the same or different meas-
urement tools; and studies of treatment evaluated poten-
tial benefits and harms for those diagnosed by the new
criterion and not diagnosed by the old criterion.
Results
Studies considered by the committee during revisions to
the age of onset criterion
We identified one document that we considered the key
document describing the evidence to support the ADHD
criteria revision process [13] (Additional file 1: Add-
itional Document). The document refers to a systematic
literature review published by the “workgroup age-of-
onset subcommittee” [14] and one published study [15]
as evidence for the change to the age of onset criterion.
The review included 32 studies related to the age of on-
set criterion of varying designs and with different objec-
tives. Based on these studies, the Committee
commented on a) the magnitude of change (to the cri-
terion), b) the reason/evidence for change, c) the poten-
tial negative consequences considered and d) additional
objections and response. This key document had been
available previously on the American Psychiatric Associ-
ation (APA) website, but is no longer publicly available.
On full text review of the 33 studies referred to by the
key document, 17 studies addressing the checklist items
were categorised and analysed (Fig. 1) [15–31].
Studies relevant to the age of onset criterion and the
checklist items published between 1990 and 2013
Our searches of the available literature found 20 relevant
studies (Fig. 1) [15–34]. We did not locate any studies of
prevalence, precision, benefit or harm additional to those
used by the Committee. However, we identified a further
3 studies related to prognosis [32–34].
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Risk of bias and strength of evidence of the included
studies
The published form of the literature review [14] refer-
enced in the key document is a 2-page document. It pro-
vides a link to a supplementary online table that
describes some features of the included studies (study
objective, source of age of onset information, DSM ver-
sion, study groups and results). We assessed the litera-
ture review as low quality according to the AMSTAR-2
quality assessment tool for systematic reviews [8] (Add-
itional file 1: Table S4). The review did not meet 11 of
the 13 applicable AMSTAR-2 items (of the 16
AMSTAR-2 items, 3 were not applicable as no meta-
analysis was conducted): it did not specify a research
question, outline apriori methods, explain how studies
were selected and included, extract data in duplicate, list
and justify excluded studies, describe included studies
sufficiently, assess risk of bias of the included studies or
account for risk of bias when interpreting the results or
explain heterogeneity. In addition, funding sources for
the included studies and the review authors’ potential
conflict of interest were not reported (Item 10 and 16).
The review partially met, or met, only two AMSTAR-2
criteria: the comprehensiveness of the search strategy
and duplicate study selection. Flaws in the conduct or
reporting of several critical domains of bias suggest that
the review may not provide an accurate and comprehen-
sive summary of the available studies.
Analysis of studies assessing prevalence
The key document included a primary study asses-
sing the effect of the change in the age of onset cri-
terion on prevalence using a prospective cohort
study of 2322 British twins assessed at 7 and 12
years of age using information from mothers and
teachers [15]. At age 12, 66 children (3.3%) met the
study criteria for ADHD (mother or teacher report
of six or more inattentive and/or six or more
hyperactivity-impulsivity symptoms) with age of on-
set of symptoms before 7 years. An additional 2 chil-
dren presented with symptoms meeting the ADHD
diagnostic criteria between age 7 and 12. This study
estimated that the increase in the prevalence of
ADHD because of the change in the criterion would
be 0.1% (Additional file 1: Table S5a).
The research evidence related to the effect on
prevalence used to support the change to the age of
onset criterion consists of a single study. We
assessed the risk of bias in this study as low (Add-
itional file 1: Table S5b). However, there is consider-
able uncertainty about the applicability of the
evidence because of the type of participants (twins),
failure to assess the effects on prevalence of the
change to both the age and impairment require-
ments of the criterion, the prospective measurement
of symptom onset and the low prevalence of ADHD
in the population studied (3.3%).
Fig. 1 Categorisation of studies addressing checklist items and overlap with studies used by the Committee
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Analysis of studies assessing prognosis
The key document considered the prognostic ability of
the age of onset criterion using 11 studies [16–26] iden-
tified by the literature review [14] and we identified an
additional 3 studies [32–34] in our searches (Fig. 1).
These studies of cross-sectional and cohort design in
child, adolescent or adult populations, compared a range
of outcomes between variably defined groups with ‘early’
onset of ADHD symptoms or impairing symptoms
(sometimes termed ‘Full ADHD’) and ‘late’ onset of
ADHD symptoms or impairing symptoms (Additional
file 1: Table S6a). Study results were mixed, with prog-
nosis varying between ‘early’ and ‘late’ symptom onset
groups for the same outcomes between studies, and for
different outcomes within studies. Some of these studies
were mentioned and referenced in the text of the litera-
ture review [14], while others appeared in the supple-
mentary online table only.
The research evidence related to the prognostic ability
of the age of onset criterion consists of multiple studies
that we assessed to be at moderate or high risk of bias
on 3 or more of the 6 domains of bias [11]. Risk of bias
from confounding was present in most studies, and the
potential for selective reporting or absence of an appro-
priate statistical model in all studies (Additional file 1:
Table S6b). The possibility of bias arising from the retro-
spective recall of the age of symptom onset was judged
to be considerable in the studies of cross-sectional de-
sign. In assessing the strength of the evidence, there was
inconsistency in the results of studies of similar design,
and the applicability of these studies is questionable as
many were performed in clinical samples and none eval-
uated the prognostic ability of the criterion in individ-
uals identified by the new but not old (DSM-IV-TR) age
of onset criterion.
Analysis of studies assessing precision
The key document considered 3 studies [27–29] in-
cluded in the literature review [14] related to the preci-
sion of methods of measuring age of onset. These
studies evaluated the reporting of the date, or the age of
onset of symptoms or behaviours by the same informant
(using the same or different method of obtaining onset
information) at different time intervals (1 week, 1 year
and 5 years) (Additional file 1: Table S7a). These studies
found poor to moderate agreement on: the date of
symptom onset when data were collected at interviews
1 week apart; but reasonable stability of mothers report-
ing DSM-III symptoms over a 1-year period; and parent
or self-reports of ‘later’ age of onset of impairing symp-
toms after a 5-year interval.
The research evidence related to the precision that the
Committee considered in changing the age of onset cri-
terion was not applicable to the checklist item. The item
requires evaluation of the agreement between the same
clinicians at different times (repeatability), and between
different clinicians (reproducibility) on their judgment of
whether an individual meets, or does not meet, the new
age of onset criterion. None of the available studies pro-
vide this information. In addition, we assessed the stud-
ies used by the Committee to be at high or unclear risk
of bias because the study population was not suited to
evaluate the precision of the age of onset criterion, the
interviewers were not those who would perform the test
in everyday practice, and because of the availability of
other clinical information which may influence assessors
coding of the date or age of onset. (Additional file 1:
Table S7b).
Analysis of studies assessing benefits and/or harms
The Committee considered 2 studies [30, 31] relating to
the potential benefits and harms of treatment. The first
of these single arm studies evaluated the response to
methylphenidate among a population of adults with ‘late
onset’ ADHD [30]. In the second, children, adolescents
and adults were treated with methylphenidate and treat-
ment response was compared between participants
meeting DSM-IV ADHD criteria and participants meet-
ing all criteria except symptom onset before age 7 [31]
(Additional file 1: Table S8a). The adverse effects of the
medication were reported in one study. There were no
studies evaluating the potential harms arising from a
diagnosis of ADHD according to the new age of onset
criterion or arising from treatment of individuals classi-
fied by the new criterion.
To assess risk of bias in single-arm studies included in
systematic reviews, we used a tool currently being trialed
by the Cochrane Kidney Group (Beller, E. Personal com-
munication. 2018. Feb 14). The research evidence related
to the benefit or harm for individuals diagnosed by the
new age of onset criterion consists of two single arm
studies that are at high risk of bias due to lack of a con-
trol group, selection bias, lead time bias, bias due to ad-
junctive therapies, attrition bias and selective reporting
of outcomes (Additional file 1: Table S8b). Further, the
applicability of the studies to the checklist item is uncer-
tain as the studies do not evaluate the benefits or harms
arising from the treatment of those individuals identified
by the new, but not old age of onset criterion (that is,
the additional ‘milder’ and ‘older’ individuals identified
by the new but not old criterion).
Discussion
We used the Checklist for Modifying Disease Definitions
as a framework to examine the research informing
changes to the DSM-IV-TR ADHD age of onset criter-
ion. We found that the research evidence used by the
Committee to inform the change to the age of onset
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criterion was limited; often at high risk of bias and/or of
limited applicability. No research was found to support
the removal of the requirement for impairment compo-
nent of the age of onset criterion. The process used to
inform the changes to the criterion was not transparent,
with only limited information publicly available and
some of the previously available information no longer
available. As outlined in the key document (Additional
Document), the age of onset criterion included in the
DSM-IV-TR has been criticized as being arbitrary, with
evidence that the age 7 cut-off is not valid [35, 36]. This
evidence would be considered in the checklist by the
third item; What is the trigger for considering the modi-
fication of the disease definition?
Our results should be interpreted with consideration
of the study’s strengths and limitations. Our searches
were limited by searching only one database with some
reference checking. This search was not highly sensitive,
and we may have missed some studies. However, we did
find all of the studies that were reported in the literature
review [14] and considered by the committee. Further,
we assessed the quality of the available studies related to
age of onset with relevant risk of bias tools and evalu-
ated the body of research evidence related to the Check-
list items.
While it is evident that the Committee endeavored to
identify available research relating to the age of onset
criterion by performing a literature review, details re-
garding study planning, the location and selection of
available research, attempts to assess the quality of the
research and to describe how it was taken into consider-
ation was either not described or was not done. It is pos-
sible that methods were more rigorous than indicated in
the publicly available document, but without adequate
reporting we cannot be sure that the methods of the re-
view were reliable and the conclusions trustworthy.
The available documentation indicates that the Com-
mittee considered the potential increase in prevalence of
ADHD diagnosis as a result of the change to the age of
onset criterion, but used the results of a single cohort
twin study containing 68 children with ADHD [15] to
conclude that the ‘impact on prevalence will be negli-
gible’. Our assessment of this study found that the study
design does not allow a full assessment of the impact of
the change to the age of onset criterion on prevalence.
While providing insight into potential changes in preva-
lence resulting from a change to the age of symptom on-
set, the effect on prevalence arising from both the
change to age and impairment cannot be determined
from this study. The prevalence change estimate from
this study contrasts with a cross-sectional study in ado-
lescents using retrospective recall of symptom onset by a
parent, and a prospective cohort study of school aged
children published after DSM-5, that report larger
changes to prevalence with the new age of onset criter-
ion [37, 38]. However, these studies also only evaluate
the effect of the change in age threshold and not both
the change in age and impairment requirements.
The available studies of prognosis and benefit or harm
were generally at high risk of bias and did not assess the
outcomes of, or potential benefits and harms of treat-
ment, to those identified by the new but not old age of
onset criterion. Further, no studies informed the preci-
sion of the new age of onset criterion. Again without
studies considering the removal of the impairment re-
quirement, as well as age of onset, the effect on prognos-
tic ability from both changes cannot be fully elucidated
or understood.
Changes to the way that health conditions are defined
are likely to have widespread and significant conse-
quences, and should be based on the highest quality of
evidence possible. Proposed changes should be field
tested in conditions that are as similar as possible to the
conditions where the definition will be used, including
community settings, to assess the effects on prevalence
and diagnostic precision. Prognosis should be assessed
by longitudinal cohort studies that have measured the el-
ements used to define the criteria and have tracked clin-
ical and other outcomes of interest over time. Benefits
and harms from changes need to be carefully considered,
preferably through the conduct of randomised controlled
trials. It cannot be assumed that the benefits and harms
seen in those diagnosed using a previous definition will
apply to those diagnosed using the new definition.
Committees and panels need to report any research
used to inform their decisions around changed definitions,
critically assess and synthesise available research using sys-
tematic and justifiable methods, and provide this informa-
tion to clinicians and relevant groups. The Checklist for
Modifying Disease Definitions, a world-first evidence in-
formed document, is designed to facilitate this process but
is likely to require committee members with methodo-
logical and epidemiological expertise in its application.
Conclusion
Changing the definition of health conditions places
many people at risk of unnecessary diagnosis and treat-
ment. This study found that changes to the DSM-IV
ADHD age of onset criterion that widened the definition
were based on research that was judged to be at high
risk of bias and/or to have poor applicability. The re-
search did not inform of the effects of changes to both
the age and the impairment components of the criterion
on the prevalence of ADHD. With such limited evidence
on the effects of changes on prevalence, prognosis, preci-
sion, benefits and harms, the Committee could have
chosen not to change the age of onset criterion, or, at
the most, change the age component of the criterion,
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but retain the impairment component. Rigor and trans-
parency in the processes around modifying health condi-
tion definitions should be expected. Committees and
panels need to document reasons for any proposed
changes, carefully report any research used to inform
their decisions, and critically assess and synthesize this
research using systematic and justifiable methods. As
important as process, is the documentation of that
process and details of decision making should be avail-
able to be critiqued by others. Although DSM-5 ADHD
Committee members had provisions to include com-
ments from the clinical and public communities through
public postings, this document is no longer publicly
available. When the documents were available, they were
not detailed, and so decisions remain opaque. Revisions
of DSM are regular, planned events. The Checklist
should be used to inform further revisions and to facili-
tate the appropriate design and conduct of research that
can address the effects of any future proposed changes.
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